# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
– Data from Phase 3 ENERGIZE Study of Mitapivat in Non-Transfusion-Dependent Thalassemia to be Presented in Plenary Session – –...
Goldman Sachs analyst Salveen Richter maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Neutral and raises the price targ...
Agios Pharmaceuticals (NASDAQ:AGIO) reported quarterly losses of $(1.45) per share which beat the analyst consensus estimate of...
Cantor Fitzgerald analyst Eric Schmidt reiterates Agios Pharmaceuticals (NASDAQ:AGIO) with a Overweight.
RBC Capital analyst Gregory Renza maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Outperform and lowers the price targe...
Agios Pharmaceuticals (NASDAQ:AGIO) reported quarterly sales of $7.10 million which missed the analyst consensus estimate of $7...
Companies Reporting Before The Bell • Cognex (NASDAQ:CGNX) is estimated to report quarterly earnings at $0.10 per share on rev...